This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Unresectable Advanced Cancer
and you are
between 18 and 75
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

MM-398 (also known as PEP02) is nanoliposomal encapsulated irinotecan: the liposomal formulation is designed to extend plasma circulation and to increase accumulation in the tumor through the enhanced permeability and retention (EPR) effect. This study introduces a new concept of combining free and nanoliposomal drugs.

Provided treatments

  • Drug: MM-398
  • Drug: Irinotecan
  • Drug: Leucovorin (LV)
  • Drug: 5-fluorouracile (5-FU)
  • Drug: bevacizumab
  • Drug: MM-398

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02640365. The sponsor of the trial is GERCOR - Multidisciplinary Oncology Cooperative Group and it is looking for 10 volunteers for the current phase.
Official trial title:
A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI